-+ 0.00%
-+ 0.00%
-+ 0.00%

Propanc Biopharma files draft information statement on restricted stock issuances

PUBT·08/05/2026 10:00:59
Listen to the news
Propanc Biopharma files draft information statement on restricted stock issuances
  • Propanc Biopharma shareholders authorized new restricted common stock issuances totaling 3.5 million shares for officers, directors, consultants, legal advisers.
  • Largest grant: 1 million restricted shares to CEO James Nathanielsz; remaining awards largely 250,000 shares each across multiple recipients.
  • Company reported 3,503,116 common shares outstanding as of July 24, 2026, before the new issuances.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036041), on August 05, 2026, and is solely responsible for the information contained therein.